New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
A committee to be formed to suggest measures for ensuring the safety of healthcare professionals
The emergence of new infections in India is a growing concern
Becomes the first rehab & recovery center in east India to earn NABH accreditation
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
The sales of medicines and other items sold through Jan Aushadhi Kendras have increased from Rs. 7.29 crore in 2014 to Rs. 1,470 crore by July 2024
Subscribe To Our Newsletter & Stay Updated
